Molecular Imaging Market Size & Growth Forecast 2027–2036, By Segments (Modality, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Molecular Imaging Market size was worth USD 9.5 billion in 2026 and is expected to grow at a 4.37% CAGR between 2027 and 2036, reaching USD 14.57 billion by 2036. The industry revenue for 2027 is estimated at USD 9.85 billion.

• Base Year Value (2026): USD 9.5 billion
• CAGR (2027-2036): 4.37%
• Forecast Year Value (2036): USD 14.57 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Molecular Imaging Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 43.88% of the market in 2026, driven by established imaging infrastructure, widespread clinical adoption, and strong utilization across oncology, cardiology, and neurology workflows.
  • Asia Pacific is expected to grow at a 5.24% CAGR as healthcare infrastructure expands, diagnostic investments increase, and specialist care adoption drives greater use of molecular imaging.

• Segment Momentum:

  • SPECT held a 45.9% market share in 2026 due to its broad clinical familiarity, integration with existing nuclear medicine infrastructure, and sustained use across routine diagnostic imaging workflows.
  • Diagnostic imaging centers are growing fastest as healthcare shifts toward specialized outpatient services offering streamlined workflows, faster scheduling, and expanded access to molecular imaging outside hospital settings.

• Market Expansion Drivers:

  • Rising chronic diseases such as cancer and neurological disorders increasing imaging demand.
  • Growth of hybrid PET-SPECT/CT systems and AI-enabled imaging diagnostics.
  • Expanding government and institutional funding for cancer research and radiology innovation.

• Leading Market Participants:

  Major companies in the molecular imaging market include Siemens Healthineers AG (Germany), GE HealthCare (United States), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Bruker Corporation (United States), Shimadzu Corporation (Japan), Mediso Ltd. (Hungary), United Imaging Healthcare Co., Ltd. (China), Cubresa Inc. (Canada), Positron Corporation (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 9.5 billion
  • 2027 Estimated Market Size: USD 9.85 billion.
  • Projected Market Size: USD 14.57 billion by 2036
  • Growth Forecasts: 4.37% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Single Photon Emission Computed Tomography (SPECT) (Modality) | Hospitals (End Use) | Oncology (Application)
  • Emerging Opportunity Segment: Nuclear Magnetic Resonance (NMR) Spectrometer (Modality) | Diagnostic Imaging Centers (End Use) | Cardiovascular (Application)

Market Growth Drivers and Industry Trends

Rising chronic diseases such as cancer and neurological disorders increasing imaging demand

The increasing prevalence of cancer and neurological disorders will propel the molecular imaging market as clinicians require more sophisticated methods to identify disease activity, characterize abnormalities, and monitor treatment response. Molecular imaging can provide functional and biological information that complements conventional anatomical imaging, making it valuable for detecting disease processes and evaluating changes over the course of care. Growing clinical attention toward earlier diagnosis and personalized treatment approaches is also encouraging the use of imaging techniques capable of revealing physiological and molecular characteristics. This expanding diagnostic and monitoring requirement across oncology and neurology is increasing utilization of molecular imaging technologies in clinical settings.

Growth of hybrid PET-SPECT/CT systems and AI-enabled imaging diagnostics

Integration of advanced modalities is reshaping the molecular imaging market by combining functional information with detailed anatomical visualization and computational analysis. Hybrid PET-SPECT/CT systems can provide complementary diagnostic information within integrated imaging workflows, helping clinicians localize abnormalities and interpret complex disease patterns more effectively. At the same time, artificial intelligence can assist with image reconstruction, segmentation, lesion identification, quantitative assessment, and workflow optimization, potentially improving consistency and reducing the burden of image interpretation. The combination of hybrid imaging and AI-enabled capabilities is expanding the clinical utility of molecular imaging across increasingly complex diagnostic applications.

Expanding government and institutional funding for cancer research and radiology innovation

Increased government and institutional support for medical research is creating opportunities for innovation and infrastructure development across the molecular imaging market, particularly in cancer research and advanced radiology. Funding can support the development of new imaging approaches, improved diagnostic technologies, radiotracer research, and clinical investigation of emerging applications. Research institutions and healthcare organizations can also use such resources to strengthen imaging capabilities and integrate newer technologies into diagnostic programs. Greater investment in translational research and advanced radiological techniques supports continued development of molecular imaging applications across research and clinical environments.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising chronic diseases such as cancer and neurological disorders increasing imaging demand	2.00%	High	North America, Europe	High	Near Term
Growth of hybrid PET-SPECT/CT systems and AI-enabled imaging diagnostics	1.60%	High	North America, Asia Pacific	High	Mid Term
Expanding government and institutional funding for cancer research and radiology innovation	1.30%	High	North America, Europe	High	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

In the molecular imaging market, North America accounted for the largest share of 43.88% in 2026, reflecting strong investment in advanced diagnostic technologies, established research capabilities, and broad access to specialized imaging services. Molecular imaging is increasingly valued for its ability to provide detailed insights into biological processes, supporting applications across oncology, cardiology, neurology, and drug development. Advanced healthcare infrastructure, growing emphasis on precision medicine, and continued clinical research are reinforcing demand for sophisticated molecular imaging technologies.

Asia Pacific is emerging as the fastest-growing region as healthcare providers increase investments in advanced diagnostic infrastructure and precision-oriented medical technologies. Rising disease burden, improving access to specialized imaging facilities, and growing research activity are expanding the potential applications of molecular imaging. Greater awareness of early disease detection and increasing adoption of personalized healthcare approaches are also encouraging healthcare institutions to integrate advanced imaging modalities into diagnostic and therapeutic workflows.

Key Country Insights

United States

AI-integrated imaging pipelines

The molecular imaging market in the United States is driven by integration of AI-assisted image reconstruction and radiopharmaceutical innovation in oncology and neurology workflows. In the United States, hospitals and research centers increasingly focus on hybrid imaging systems combining PET/CT and PET/MR to streamline diagnostic accuracy while supporting personalized treatment planning and trial-based imaging protocols.

Japan

Diagnostic miniaturization focus

Japan molecular imaging market prioritizes compact, high-efficiency diagnostic systems suited to aging population care settings. In Japan, hospitals focus on rapid PET imaging workflows and integration with digital diagnostics platforms, while manufacturers emphasize lower-dose radiotracers and space-efficient scanner designs for urban healthcare infrastructure.

South Korea

Hospital imaging digitization

South Korea molecular imaging market is shaped by rapid hospital digitization and strong adoption of advanced imaging IT systems. In South Korea, tertiary hospitals invest in integrated imaging networks linking nuclear medicine with electronic health records, improving diagnostic turnaround times and supporting expanding oncology screening programs.

Germany

Clinical radiopharma workflows

Germany molecular imaging market is anchored in structured clinical pathways and strong radiopharmaceutical manufacturing alignment. In Germany, hospital networks emphasize standardized PET/SPECT protocols, with growing collaboration between research institutes and imaging equipment providers to improve diagnostic reproducibility and expand precision oncology applications within regulated healthcare environments.

France

Nuclear medicine adoption

France molecular imaging market reflects strong public healthcare system integration with nuclear medicine services. In France, academic hospitals emphasize PET-based research in oncology and neurology, while adoption is guided by reimbursement frameworks that support targeted use of advanced imaging for complex diagnostic cases and treatment monitoring.

Italy

Diagnostic center networks

Italy molecular imaging market is characterized by specialized diagnostic centers and uneven regional access to advanced imaging infrastructure. In Italy, leading hospitals concentrate PET and SPECT capabilities in urban hubs, focusing on oncology diagnostics while gradually expanding radiopharmaceutical availability and improving inter-hospital referral imaging networks.

Segment Leadership and Growth Trends

 

Modality Segment Analysis: Single Photon Emission Computed Tomography (SPECT) (Largest Segment) vs Nuclear Magnetic Resonance (NMR) Spectrometer (Fastest-Growing Segment)

Single photon emission computed tomography (SPECT) dominated the molecular imaging market in 2026, accounting for 45.9% share, supported by its established role in visualizing physiological and functional processes within the body. SPECT can provide information about tissue activity and organ function that complements structural imaging, making it valuable for disease assessment and treatment planning. Its established clinical infrastructure, broad diagnostic applications, and integration with complementary imaging approaches continue to support strong utilization.

Nuclear magnetic resonance (NMR) spectrometers are gaining interest as molecular analysis increasingly emphasizes detailed characterization of biological structures and metabolic processes. NMR-based techniques can provide valuable molecular-level information without relying on ionizing radiation, supporting research and advanced diagnostic investigations. Increasing demand for precise molecular characterization and greater integration of analytical technologies with biomedical research is creating opportunities for expanded application of NMR spectrometry.

End Use Segment Analysis: Hospitals (Largest Segment) vs Diagnostic Imaging Centers (Fastest-Growing Segment)

Hospitals held the largest share of the molecular imaging market in 2026, reflecting their ability to combine advanced imaging infrastructure with specialist expertise and comprehensive patient management. Molecular imaging is particularly valuable when diagnostic information must be integrated with treatment planning, disease monitoring, and multidisciplinary clinical assessment. The concentration of complex cases and specialized services within hospitals therefore supports their continued importance as major end users of molecular imaging technologies.

Diagnostic imaging centers are expanding their presence as healthcare delivery increasingly incorporates specialized outpatient diagnostic services. Dedicated imaging facilities can support efficient scheduling, focused workflows, and broader patient access to advanced diagnostic technologies. As demand grows for timely, specialized imaging and healthcare systems continue to emphasize outpatient pathways, diagnostic imaging centers are becoming increasingly relevant end users of molecular imaging solutions.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Modality	Molecular Ultrasound Imaging, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR) Spectrometer, Others	Single Photon Emission Computed Tomography (SPECT)	Nuclear Magnetic Resonance (NMR) Spectrometer
End Use	Hospitals, Diagnostic Imaging Centers, Research Institutes	Hospitals	Diagnostic Imaging Centers
Application	Cardiovascular, Neurology, Oncology, Respiratory, Gastrointestinal	Oncology	Cardiovascular

Competitive Landscape and Market Positioning

Top players in the molecular imaging market:

1. Siemens Healthineers AG (Germany)

2. GE HealthCare (United States)

3. Koninklijke Philips N.V. (Netherlands)

4. Canon Medical Systems Corporation (Japan)

5. Bruker Corporation (United States)

6. Shimadzu Corporation (Japan)

7. Mediso Ltd. (Hungary)

8. United Imaging Healthcare Co. Ltd. (China)

9. Cubresa Inc. (Canada)

10. Positron Corporation (United States)

The molecular imaging market is evolving through the integration of advanced diagnostic modalities that enhance disease detection at a molecular level. Collaborative innovation efforts are supporting more comprehensive imaging ecosystems. Research advancements continue to improve accuracy, resolution, and functional imaging capabilities.

Industry Development/News

Company Name	Date	Key Development
Lantheus Holdings	Dec-25	Lantheus agreed to acquire Life Molecular Imaging for up to $750 million. This acquisition incorporates the approved PET imaging agent Neuraceq into its portfolio, significantly strengthening the company’s competitive position and diagnostic capabilities within the neurodegenerative disease and molecular imaging markets.
Siemens Healthineers	Dec-25	Siemens Healthineers finalized the acquisition of Novartis’ imaging unit for $223 million. This strategic move enhances the company’s PET radiopharmacy infrastructure and expands its production capacity for radiopharmaceuticals, directly supporting the integration of molecular imaging and targeted therapeutic workflows.
Bayer	Dec-25	Bayer entered into agreements to acquire two investigational pan-amyloid molecular imaging agents from Attralus. The transaction marks a targeted expansion of Bayer’s diagnostic portfolio and aligns with its strategic focus on advancing cardiovascular precision medicine through integrated molecular imaging solutions.
Minerva Imaging	Dec-25	Private equity firm Nordic Capital completed an investment in Minerva Imaging. The funding is intended to accelerate the company’s growth and operational scale, providing the financial support necessary to expand its research services and capabilities within the highly specialized molecular imaging sector.
United Imaging	Dec-25	United Imaging launched the uMI Panvivo and uMI Panorama GS systems, alongside a new nuclear medicine AI solution. These product introductions, coupled with new European strategic partnerships, reflect an aggressive expansion of the company’s molecular imaging portfolio and a broader initiative to increase its regional market penetration.
GE HealthCare	Dec-25	GE HealthCare expanded its research partnership with Stanford Radiology to establish a specialized Center of Excellence. The collaboration focuses on advancing innovation across molecular imaging, pharmaceutical diagnostics, and advanced modalities like MRI and CT, reinforcing the company's long-term technology development and research pipeline.
GE HealthCare	Nov-25	OhioHealth Doctors Hospital expanded its clinical infrastructure by deploying GE HealthCare’s StarGuide SPECT/CT system. This installation enhances the facility’s molecular imaging throughput and diagnostic precision, supporting advanced patient care workflows in oncology, neurology, and cardiovascular medicine through high-end imaging technology.
Siemens Healthineers	Jun-24	The U.S. FDA cleared the Biograph Trinion, a PET/CT scanner designed for high energy efficiency and optimized clinical performance. By lowering lifetime operational costs while providing broad clinical application versatility, this launch addresses the industry demand for more sustainable and cost-effective molecular imaging solutions.
Spectrum Dynamics	Oct-22	Spectrum Dynamics introduced the VERITON-CT 400 Series, utilizing 360° CZT-based, wide-bore solid-state detector technology. This development marks a significant advancement in digital nuclear medicine, enabling the imaging of high-energy isotopes across total-body, cardiac, and neurological applications, thereby improving image quality and clinical versatility.
Positron Corporation	Jun-24	Positron Corporation announced the sale and upcoming installation of its Attrius PET System. As a dedicated 2D quantitative PET scanner tailored specifically for nuclear cardiology, this deployment highlights the continued demand for specialized, high-resolution imaging equipment focused on addressing specific clinical segments within the broader molecular imaging market.